Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
189.27B
Market cap189.27B
Price-Earnings ratio
27.16
Price-Earnings ratio27.16
Dividend yield
2.71%
Dividend yield2.71%
Average volume
2.94M
Average volume2.94M
High today
$353.25
High today$353.25
Low today
$346.93
Low today$346.93
Open price
$348.71
Open price$348.71
Volume
3.27M
Volume3.27M
52 Week high
$353.25
52 Week high$353.25
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

With a market cap of 189.27B, Amgen(AMGN) trades at $351.88. The stock has a price-to-earnings ratio of 27.16 and currently yields dividends of 2.7%.

On 2026-01-28, Amgen(AMGN) stock moved within a range of $346.93 to $353.25. With shares now at $351.88, the stock is trading +1.4% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 3.27M, compared to an average daily volume of 2.94M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $353.25 and a low of $261.43.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $353.25 and a low of $261.43.

AMGN News

Simply Wall St 15h
Is It Time To Reassess Amgen After Strong Multi Year Share Price Gains

If you are wondering whether Amgen's current share price lines up with its underlying value, you are not alone. This article is built to walk you through that q...

Is It Time To Reassess Amgen After Strong Multi Year Share Price Gains
TipRanks 18h
Amgen Advances Teprotumumab Program With Completed Phase 1 Study in Healthy Chinese Volunteers

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

TipRanks 2d
Amgen price target raised to $390 from $380 at UBS

UBS raised the firm’s price target on Amgen (AMGN) to $390 from $380 and keeps a Buy rating on the shares. The U.S. Pharmaceuticals and Biotechnology group is e...

Analyst ratings

48%

of 33 ratings
Buy
45.5%
Hold
48.5%
Sell
6.1%

More AMGN News

Simply Wall St 3d
Will 340B Lawsuit Over Drug Discounts Shift Amgen's Access Strategy And Investment Narrative?

Sagebrush Health Services has filed a lawsuit in California Superior Court against Amgen Inc., alleging unlawful termination of 340B drug discounts and improper...

Will 340B Lawsuit Over Drug Discounts Shift Amgen's Access Strategy And Investment Narrative?
Simply Wall St 4d
Assessing Amgen Valuation After The New Sagebrush 340B Lawsuit

Advertisement Why the Sagebrush lawsuit matters for Amgen stock The new lawsuit from Sagebrush Health Services puts Amgen (AMGN) and its role in the 340B Drug...

Assessing Amgen Valuation After The New Sagebrush 340B Lawsuit
Seeking Alpha 5d
Amgen snaps after six straight sessions of gains

Amgen (NASDAQ:AMGN) snapped six consecutive sessions of gains, as the company’s shares closed 0.66% lower at $344.78 on Friday. In the preceding six sessions,...

Amgen snaps after six straight sessions of gains
Simply Wall St 6d
Amgen Faces 340B Lawsuit Spotlighting Drug Pricing And Investor Risks

Sagebrush Health Services has filed a lawsuit against Amgen (NasdaqGS:AMGN), accusing the company of improperly ending discounted drug sales under the federal 3...

Amgen Faces 340B Lawsuit Spotlighting Drug Pricing And Investor Risks

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.